|
|
|
Volumn 113, Issue 1, 1999, Pages 18-19
|
|
New treatments in severe sepsis. Scientific, economic and ethical aspects;Nuevos tratamientos de la sepsis grave. Una encrucijada cientifica, economica y etica
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DELTIBANT;
GINKGOLIDE B;
IBUPROFEN;
NONSTEROID ANTIINFLAMMATORY AGENT;
PROTEIN C;
TUMOR NECROSIS FACTOR;
ANTIINFLAMMATORY ACTIVITY;
CONTROLLED STUDY;
COST EFFECTIVENESS ANALYSIS;
ECONOMIC ASPECT;
EDITORIAL;
ETHICS;
EUROPE;
HUMAN;
HUMAN CELL;
HUMAN TISSUE;
INCIDENCE;
INTENSIVE CARE;
MAJOR CLINICAL STUDY;
SEPSIS;
UNITED STATES;
COST OF ILLNESS;
ETHICS, MEDICAL;
HUMANS;
SEPSIS;
SEVERITY OF ILLNESS INDEX;
|
|
EID: 0033549307
PISSN: 00257753
EISSN: None
Source Type: Journal
DOI: None Document Type: Editorial |
|
Times cited : (4)
|
|
References (24)
|
